Veru Inc
$ 2.42
0.00%
04 Dec - close price
- Market Cap 38,841,900 USD
- Current Price $ 2.42
- High / Low $ 2.50 / 2.38
- Stock P/E 0.40
- Book Value 1.05
- EPS 6.00
- Next Earning Report 2025-12-15
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.52 %
- ROE -1.06 %
- 52 Week High 14.20
- 52 Week Low 2.11
About
Veru Inc. is a clinical-stage biopharmaceutical company based in Miami, Florida, focused on developing innovative therapeutics primarily for oncology and unmet medical needs. The company's robust pipeline features a range of drug candidates designed to tackle various cancers, emphasizing both novel therapies and improvements to existing treatments. By leveraging its proprietary technologies and scientific acumen, Veru is dedicated to advancing patient care and delivering potentially life-saving solutions while enhancing shareholder value. With a commitment to addressing critical healthcare challenges, Veru positions itself at the forefront of biopharmaceutical innovation.
Analyst Target Price
$19.75
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-12-01 | 2025-08-12 | 2025-05-06 | 2025-02-06 | 2024-12-05 | 2024-08-08 | 2024-04-01 | 2024-02-14 | 2023-12-08 | 2023-08-10 | 2023-05-11 | 2023-02-09 |
| Reported EPS | 0 | -0.5 | -0.0603 | -0.0713 | -0.052 | -0.07 | -0.08 | -0.08 | -0.12 | -0.13 | -0.48 | -0.46 |
| Estimated EPS | -0.0567 | -0.05 | -0.05 | -0.08 | -0.08 | -0.06 | -0.1 | -0.1 | -0.23 | -0.2 | -0.33 | -0.38 |
| Surprise | 0.0567 | -0.45 | -0.0103 | 0.0087 | 0.028 | -0.01 | 0.02 | 0.02 | 0.11 | 0.07 | -0.15 | -0.08 |
| Surprise Percentage | 100% | -900% | -20.6% | 10.875% | 35% | -16.6667% | 20% | 20% | 47.8261% | 35% | -45.4545% | -21.0526% |
Next Quarterly Earnings
| Sep 2025 | |
|---|---|
| Reported Date | 2025-12-15 |
| Fiscal Date Ending | 2025-09-30 |
| Estimated EPS | -0.49 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | None | None | None | None | None | None | None | None | None | None |
| Amount | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.06 | $0.06 | $0.06 | $0.06 | $0.05 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VERU
2025-10-23 13:32:08
The provided news article content is unfortunately inaccessible, displaying a "403 Forbidden" error. This indicates that access to the page is restricted, and therefore, no information about Veru Inc.'s dividend prospects or technical patterns can be extracted.
2025-10-23 13:32:08
This article displays a "403 Forbidden" error, indicating that access to the content is denied. Therefore, no information about why pension funds might invest in Veru Inc. (FMW) stock is available.
2025-10-23 13:32:08
Veru Inc.'s share price increased by 29% in the last month, but it is still down 48% over the past year. The company's current price-to-sales (P/S) ratio of 3.8x is lower than the industry average, which is attributed to its past revenue shrinkage and a forecasted revenue growth of 23% per year, lagging behind the industry's 27% growth. This suggests investors are cautious due to limited future growth prospects.
2025-10-23 13:32:08
The requested content could not be retrieved due to a "403 Forbidden" error from the server. This indicates that access to the page was denied.
2025-10-23 13:32:08
This article displays a 403 Forbidden error, indicating that access to the content is restricted. Therefore, it is impossible to determine if Veru Inc. (FMW) stock will continue raising dividends or to outline any long-term growth portfolio plans. The article content is inaccessible.
2025-10-14 07:59:27
Veru Inc.'s stock (NASDAQ:VERU) recently fell below its 200-day moving average, trading as low as $4.03 before closing at $4.14. Despite this, analysts have set a consensus target price of $33.33 for the company, with ratings including three "Buy" and one "Sell." Veru also reported better-than-expected quarterly EPS of ($0.50), exceeding the consensus estimate of ($0.55).
